Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

H.C. Wainwright lowers Sol Gel Technologies shares target citing slower revenue ramp

EditorEmilio Ghigini
Published 05/20/2024, 09:34 PM
SLGL
-

On Monday, H.C. Wainwright adjusted its price target for Sol Gel Technologies Ltd. (NASDAQ:SLGL) shares, a pharmaceutical company, lowering it to $6.00 from the previous target of $9.00. Despite the reduction, the firm maintained a Buy rating on the company's stock. The revision follows a recent announcement by Sol Gel regarding a new commercial partnership.

Sol Gel disclosed late last week that it had signed an asset purchase agreement with Shenzhen Beimei Pharmaceutical Co. Ltd., a China-based company.

This deal grants Beimei the exclusive rights to commercialize Sol Gel's acne treatment, Twyneo, in mainland China, Hong Kong, Macau, Taiwan, and Israel.

In exchange, Sol Gel is set to receive upfront and milestone payments totaling $10 million, as well as royalties on net sales that could reach up to $5 million, all subject to governmental approvals.

According to the terms of the agreement, Sol Gel has received an estimated $1 million in upfront payments and anticipates additional milestone payments starting next year. This partnership aligns with Sol Gel's strategy of regional collaborations to expand the reach of its products, including Twyneo and Epsolay.

The analyst from H.C. Wainwright cited a slower revenue ramp and lower peak sales as the primary reasons for the price target adjustment. This assessment takes into account the performance of Sol Gel's drugs in the U.S. market, which are currently being commercialized by its partner, Galderma.

Sol Gel's management has signaled that the company expects to announce further regional partnerships in the months ahead, which could potentially influence the commercial trajectory of its products. The collaborations are anticipated to cover both Twyneo and Epsolay, expanding Sol Gel's global footprint.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.